AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-3. (cancelled).

4. (original) A compound that is

3-(3-bromobenzyl)-11-methyl-1,2,3,4,5,6-hexahydro-5,2-(epiminomethano)-3-benzazocine;

3-(3-bromobenzyl)-1,2,3,4,5,6-hexahydro-5,2-(epiminomethano)-3-benzazocine;

3,11-bis(3-bromobenzyl)-1,2,3,4,5,6-hexahydro-5,2-(epiminomethano)-3-benzazocine;

11-acetyl-3-(3-bromobenzyl)-1,2,3,4,5,6-hexahydro-5,2-(epiminomethano)-3-benzazocine;

or a pharmaceutically acceptable salt or stereoisomer thereof.

5. (currently amended) A pharmaceutical composition which is comprised of a compound in accordance with Claim ~~1~~ 21 and a pharmaceutically acceptable carrier.

6-8. (cancelled).

9. (currently amended) A method of treating or preventing a PK-related disorder, wherein the PK-related disorder is an IGF-1R-related disorder selected from: cancer, diabetes, a hyperproliferation disorder, and acromegaly in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of Claim ~~1~~ 21.

10. (cancelled).

11. (currently amended) A method of treating cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of Claim ~~1~~ 21.

12. (currently amended) A method of treating retinal vascularization comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compoung of Claim ~~1~~ 21.

13. (currently amended) A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim ~~1~~ 21 in combination with a second compound selected from:

1) an estrogen receptor modulator,
2) an androgen receptor modulator,
3) retinoid receptor modulator,
4) a cytotoxic agent,
5) an antiproliferative agent,
6) a prenyl-protein transferase inhibitor,
7) an HMG-CoA reductase inhibitor,
8) an HIV protease inhibitor,
9) a reverse transcriptase inhibitor, and
10) an angiogenesis inhibitor.

14. (original) The method of Claim 13, wherein the second compound is an estrogen receptor modulator selected from tamoxifen and raloxifene.

15. (currently amended) A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim ~~1~~ 21 in combination with radiation therapy.

16. (original) The method of Claim 15 wherein radiation therapy is also administered.

17. (currently amended) A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim ~~1~~ 21 and paclitaxel or trastuzumab.

18. (currently amended) A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim ~~1~~ 21 and a GPIIb/IIIa antagonist.

19. (original) The method of Claim 18 wherein the GPIIb/IIIa antagonist is tirofiban.

20. (currently amended) A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim ~~1~~ 21 in combination with a COX-2 inhibitor.

21. (new) A compound of Formula I



I

wherein:

R1 is independently selected from

1) H,
2) halo,
3) OR^4,
4) NO_2,
5) $-S(O)_mR^4$,
6) CN
7) unsubstituted or substituted C_1-C_{10} alkyl,
8) unsubstituted or substituted aryl,
9) unsubstituted or substituted C_2-C_6 alkenyl,
10) unsubstituted or substituted C_3-C_{10} cycloalkyl,
11) unsubstituted or substituted C_2-C_6 alkynyl,
12) unsubstituted or substituted heterocycle,
13) $-C(O)R^4$,
14) $C(O)OR^4$,
15) $C(O)N(R^4)_2$,

16) $S(O)_mN(R^4)_2$, and

17) $N(R^4)_2$;

R^2 is selected from

1) H,
2) C_1-C_6 alkyl, and
3) $(C=O)C_1$-C_6 alkyl,

wherein said alkyl is optionally substituted with phenyl wherein said phenyl is optionally substituted with halo;

R^3 is

1) C_1-C_6 alkyl

wherein said alkyl is optionally substituted with phenyl wherein said phenyl is optionally substituted with halo;

R^4 is independently selected from

1) H,
2) unsubstituted or substituted C_1-C_{10} alkyl,
3) unsubstituted or substituted C_3-C_{10} cycloalkyl,
4) unsubstituted or substituted aryl,
5) unsubstituted or substituted heterocycle, and
6) CF_3;

m is independently 0, 1 or 2;

s is 1 to 4;

or a pharmaceutically acceptable salt or stereoisomer thereof.